Share Twitter LinkedIn Facebook Email David I. Quinn, MD, explains his thoughts on 2nd line therapy options following I-O failure 2018 Annual Meeting.
Cell Therapy for Solid Tumors: Immunotherapy Biomarkers Anusha Kalbasi, MD MOASC [2023] Immunotherapy 2 Mins Read
